



# **Lung cancer survival rates in Poland**

## Table of Contents

<b>1. Authors</b> .....	2
2.1. Data set .....	3
2.2. Stage .....	3
2.3. Morphological type of tumor .....	3
2.4. Methods .....	3
<b>3. Results</b> .....	4
<b>4. Bibliography</b> .....	19
<b>5. List of tables</b> .....	20

## 1. Authors

prof. dr hab. n. med. Joanna Didkowska

dr n. med. Urszula Wojciechowska

mgr inż. Klaudia Barańska

mgr Marta Miklewska

mgr Paweł Olasek - technical support

## 2. Materials and methods

Poland's population in 2021 was approximately 38 million, and the crude rates of lung cancer incidence were 67.2 per 100,000 men and 42.0 per 100,000 women (Didkowska et al., 2024).

### 2.1. Data set

Data for survival analysis were obtained from the Polish National Cancer Registry database and Statistics Poland<sup>1</sup>. Life tables were downloaded from the website [lifetable.de](http://lifetable.de), whose main source of data from Poland is Statistics Poland. All selected patients were diagnosed with lung cancer in the years 2000-2021, coded according to the ICD-10 classification, code range C34.0-C34.9. The set included information on birth dates, date of diagnosis and vital status, stage of disease at diagnosis, and morphological type of cancer. The initial set consisted of 472,041 incidence cases. Patients under 20 and over 99 years of age were excluded from the set. Six hundred and seven patients (0.13% of the set) were excluded due to the inability to determine the correct age of the patient and their vital status in patients without a personal identification number (PESEL). Patients who survived for less than 31 days were also excluded from the set. The final set consisted of 408,662 incidence cases. The end date of observation was December 31, 2022.

### 2.2. Stage

A stage code was established using three fields in the patient's record: TNM, if it was not reported - stage (by the TNM classification), and in other cases, a stage code with three categories of cancer advancement: local, regional, and distant. The code "no data" was entered if the above information was missing.

To recodify the stage of cancer from the TNM classification (and the stage code resulting from the TNM code), extensive conversion rules were used, which, in simple terms, are consistent with the principle below: stage I - localized; stage II and III – regional; stage IV – distant.

### 2.3. Morphological type of tumor

The morphological type of cancer dividing cases into non-small and small cell lung cancer was coded according to the rule: M8041 - M8045 small cell lung cancer, the remaining cases - non-small cell lung cancer.

### 2.4. Methods

The nonparametric relative survival analysis with the Pohar Perme Estimator (PPE) was used to calculate the net survival of patients diagnosed with lung cancer. The R software was used to perform the analyses, using the R Package *relsurv* (Perme & Pavlic, 2018) for analyses with a total follow-up period and *stnet* (Coviello et al., 2015) command using STATA 18 software for estimating survival analysis using a life-table approach. A one-year survival analysis was performed, considering the years of observation from 2000 to 2021. For 3-year survival, the cohort net survival analysis method was performed for the years 2000-2019, and for 5-year survival, for the years 2000-2017. The estimating net survival approach was used to estimate 3- and 5-year survival for 2020-2021 and 2018-2021, respectively.

---

<sup>1</sup> <https://stat.gov.pl/en/>

### 3. Results

Table 1. Number of patients diagnosed in Poland (all ages, men+women), by stage and year

	Stage localized	Stage regional	Stage distant	Unknown stage	Total
2000	3108	4518	4662	4355	16643
2001	3195	4587	4934	4146	16862
2002	3111	4597	4812	4315	16835
2003	3220	4900	5179	3871	17170
2004	3086	5044	5352	4200	17682
2005	2927	4886	5713	4468	17994
2006	3106	4990	5677	4231	18004
2007	3385	5216	6275	3604	18480
2008	3401	5235	6684	3285	18605
2009	3413	5505	7042	3236	19196
2010	3241	5359	6930	3443	18973
2011	3188	5247	7234	3438	19107
2012	3471	5268	7681	3455	19875
2013	3200	5054	7603	3696	19553
2014	3380	5151	7716	3681	19928
2015	3638	5309	7546	3686	20179
2016	4243	5411	7681	3229	20564
2017	3994	4802	7835	2976	19607
2018	4116	5033	7746	2347	19242
2019	4278	4806	7736	3001	19821
2020	3443	4128	6754	2133	16458
2021	3530	4597	6913	2844	17884

Table 2. Number of patients diagnosed with small cell lung cancer in Poland (all ages, men+women), by stage and year

	Stage localized	Stage regional	Stage distant	Unknown stage	Total
<b>2000</b>	281	607	691	336	1915
<b>2001</b>	352	675	900	557	2484
<b>2002</b>	343	671	917	570	2501
<b>2003</b>	358	759	977	495	2589
<b>2004</b>	304	665	962	523	2454
<b>2005</b>	276	698	1009	503	2486
<b>2006</b>	321	658	945	511	2435
<b>2007</b>	346	677	1087	390	2500
<b>2008</b>	337	764	1209	331	2641
<b>2009</b>	331	820	1277	381	2809
<b>2010</b>	301	801	1220	347	2669
<b>2011</b>	288	763	1242	381	2674
<b>2012</b>	290	745	1362	387	2784
<b>2013</b>	234	763	1298	370	2665
<b>2014</b>	216	770	1415	420	2821
<b>2015</b>	202	846	1384	470	2902
<b>2016</b>	250	808	1335	339	2732
<b>2017</b>	239	750	1322	285	2596
<b>2018</b>	288	829	1360	203	2680
<b>2019</b>	235	751	1420	278	2684
<b>2020</b>	173	657	1219	189	2238
<b>2021</b>	168	751	1311	290	2520

Table 3. Number of patients diagnosed with non-small cell lung cancer in Poland (all ages, men+women), by stage and year

	Stage localized	Stage regional	Stage distant	Unknown stage	Total
<b>2000</b>	2827	3911	3971	4019	14728
<b>2001</b>	2843	3912	4034	3589	14378
<b>2002</b>	2768	3926	3895	3745	14334
<b>2003</b>	2862	4141	4202	3376	14581
<b>2004</b>	2782	4379	4390	3677	15228
<b>2005</b>	2651	4188	4704	3965	15508
<b>2006</b>	2785	4332	4732	3720	15569
<b>2007</b>	3039	4539	5188	3214	15980
<b>2008</b>	3064	4471	5475	2954	15964
<b>2009</b>	3082	4685	5765	2855	16387
<b>2010</b>	2940	4558	5710	3096	16304
<b>2011</b>	2900	4484	5992	3057	16433
<b>2012</b>	3181	4523	6319	3068	17091
<b>2013</b>	2966	4291	6305	3326	16888
<b>2014</b>	3164	4381	6301	3261	17107
<b>2015</b>	3436	4463	6162	3216	17277
<b>2016</b>	3993	4603	6346	2890	17832
<b>2017</b>	3755	4052	6513	2691	17011
<b>2018</b>	3828	4204	6386	2144	16562
<b>2019</b>	4043	4055	6316	2723	17137
<b>2020</b>	3270	3471	5535	1944	14220
<b>2021</b>	3362	3846	5602	2554	15364

Table 4. Survival rates in Poland for all stages (all ages, men+women), by year

	<b>1-year survival</b>	<b>3-year survival</b>	<b>5-year survival</b>
<b>2000</b>	41,350%	17,978%	14,911%
<b>2001</b>	42,388%	18,247%	14,472%
<b>2002</b>	41,308%	18,198%	14,418%
<b>2003</b>	41,109%	18,123%	14,378%
<b>2004</b>	40,338%	17,400%	13,700%
<b>2005</b>	42,726%	19,715%	15,834%
<b>2006</b>	42,446%	19,992%	16,072%
<b>2007</b>	43,113%	20,381%	16,596%
<b>2008</b>	43,456%	19,867%	15,849%
<b>2009</b>	42,133%	19,000%	14,677%
<b>2010</b>	43,175%	19,076%	14,983%
<b>2011</b>	43,679%	19,992%	15,499%
<b>2012</b>	44,832%	20,935%	16,202%
<b>2013</b>	45,219%	20,499%	15,468%
<b>2014</b>	44,915%	21,043%	16,040%
<b>2015</b>	46,309%	22,249%	17,569%
<b>2016</b>	47,230%	23,620%	18,674%
<b>2017</b>	46,516%	24,027%	19,054%
<b>2018</b>	47,039%	24,114%	16,910%
<b>2019</b>	48,979%	26,703%	18,650%
<b>2020</b>	48,357%	24,760%	19,280%
<b>2021</b>	48,910%	24,580%	19,180%



Table 5. Survival rates in Poland for stage localized + regionalized (all ages, men+women), by year

	<b>1-year survival</b>	<b>3-year survival</b>	<b>5-year survival</b>
<b>2000</b>	52,072%	24,600%	20,439%
<b>2001</b>	53,788%	25,619%	20,294%
<b>2002</b>	53,022%	25,859%	20,140%
<b>2003</b>	53,302%	25,687%	20,442%
<b>2004</b>	52,320%	25,284%	19,815%
<b>2005</b>	55,355%	27,345%	21,615%
<b>2006</b>	54,738%	27,334%	21,484%
<b>2007</b>	56,468%	28,545%	22,842%
<b>2008</b>	56,275%	28,022%	22,153%
<b>2009</b>	55,538%	27,590%	21,603%
<b>2010</b>	57,290%	27,905%	22,188%
<b>2011</b>	58,877%	29,995%	23,763%
<b>2012</b>	59,575%	31,489%	25,112%
<b>2013</b>	61,228%	32,452%	25,265%
<b>2014</b>	61,325%	33,394%	26,048%
<b>2015</b>	61,935%	33,857%	26,740%
<b>2016</b>	62,710%	35,931%	28,847%
<b>2017</b>	64,108%	37,614%	30,526%
<b>2018</b>	64,666%	37,013%	26,790%
<b>2019</b>	67,779%	42,079%	28,990%
<b>2020</b>	66,605%	38,880%	30,620%
<b>2021</b>	66,846%	39,290%	31,350%

Table 6. Survival rates in Poland for stage distant (all ages, men+women), by year

	<b>1-year survival</b>	<b>3-year survival</b>	<b>5-year survival</b>
<b>2000</b>	25,915%	6,570%	4,851%
<b>2001</b>	26,450%	6,316%	4,273%
<b>2002</b>	24,682%	5,734%	4,231%
<b>2003</b>	23,968%	5,459%	3,880%
<b>2004</b>	24,593%	5,495%	3,741%
<b>2005</b>	25,976%	7,059%	5,239%
<b>2006</b>	25,597%	7,389%	5,717%
<b>2007</b>	25,075%	6,808%	5,010%
<b>2008</b>	25,799%	6,694%	4,727%
<b>2009</b>	24,375%	5,678%	3,501%
<b>2010</b>	25,667%	5,941%	3,684%
<b>2011</b>	25,696%	5,617%	3,115%
<b>2012</b>	26,567%	6,210%	3,479%
<b>2013</b>	27,534%	6,155%	3,313%
<b>2014</b>	27,172%	6,256%	3,551%
<b>2015</b>	26,810%	5,797%	3,560%
<b>2016</b>	26,961%	5,697%	3,225%
<b>2017</b>	25,872%	6,212%	3,631%
<b>2018</b>	26,070%	7,369%	2,890%
<b>2019</b>	27,363%	7,889%	3,800%
<b>2020</b>	29,097%	7,510%	4,550%
<b>2021</b>	30,223%	7,800%	4,660%

Table 7. Survival rates in Poland for stage unknown (all ages, men+women), by year

	<b>1-year survival</b>	<b>3-year survival</b>	<b>5-year survival</b>
<b>2000</b>	39,098%	18,595%	16,001%
<b>2001</b>	39,955%	18,608%	15,682%
<b>2002</b>	38,926%	18,412%	15,559%
<b>2003</b>	38,466%	19,203%	15,707%
<b>2004</b>	37,208%	17,309%	14,556%
<b>2005</b>	42,057%	22,557%	19,275%
<b>2006</b>	41,533%	22,853%	19,613%
<b>2007</b>	42,645%	24,531%	21,863%
<b>2008</b>	45,681%	25,232%	21,906%
<b>2009</b>	43,832%	24,316%	19,911%
<b>2010</b>	43,154%	23,461%	19,729%
<b>2011</b>	44,227%	25,697%	21,284%
<b>2012</b>	48,142%	26,972%	21,949%
<b>2013</b>	45,847%	23,313%	18,593%
<b>2014</b>	44,075%	23,417%	19,028%
<b>2015</b>	48,296%	27,753%	23,986%
<b>2016</b>	49,163%	29,442%	25,008%
<b>2017</b>	48,864%	30,767%	25,754%
<b>2018</b>	47,532%	29,095%	23,950%
<b>2019</b>	47,790%	28,654%	24,040%
<b>2020</b>	44,571%	25,920%	21,380%
<b>2021</b>	43,085%	23,870%	19,470%

Table 8. Survival rates in Poland for all stages with small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	40,000%	10,344%	7,742%
<b>2001</b>	40,707%	9,847%	6,805%
<b>2002</b>	40,027%	8,916%	6,565%
<b>2003</b>	37,836%	9,577%	7,251%
<b>2004</b>	38,780%	10,340%	7,689%
<b>2005</b>	39,002%	10,868%	8,174%
<b>2006</b>	39,482%	11,586%	8,585%
<b>2007</b>	38,353%	11,159%	8,391%
<b>2008</b>	38,164%	9,945%	7,215%
<b>2009</b>	38,296%	8,774%	5,924%
<b>2010</b>	39,758%	10,191%	7,104%
<b>2011</b>	39,366%	9,994%	6,928%
<b>2012</b>	38,884%	11,373%	8,678%
<b>2013</b>	39,286%	10,554%	7,554%
<b>2014</b>	36,924%	9,729%	6,489%
<b>2015</b>	37,683%	9,807%	7,500%
<b>2016</b>	38,291%	10,247%	7,124%
<b>2017</b>	34,631%	10,404%	7,373%
<b>2018</b>	37,360%	10,850%	6,480%
<b>2019</b>	38,760%	10,761%	7,820%
<b>2020</b>	39,046%	10,790%	7,990%
<b>2021</b>	38,353%	10,320%	7,310%

Table 9. Survival rates in Poland for stage localized + regionalized with small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	49,654%	14,643%	11,373%
<b>2001</b>	51,750%	15,282%	10,366%
<b>2002</b>	51,483%	13,294%	10,302%
<b>2003</b>	49,020%	13,512%	10,619%
<b>2004</b>	51,116%	16,801%	12,305%
<b>2005</b>	51,269%	15,528%	10,845%
<b>2006</b>	51,717%	15,993%	10,754%
<b>2007</b>	51,884%	16,744%	12,691%
<b>2008</b>	49,133%	14,982%	11,202%
<b>2009</b>	51,455%	13,744%	9,489%
<b>2010</b>	52,089%	16,152%	11,256%
<b>2011</b>	53,323%	17,129%	11,967%
<b>2012</b>	52,679%	18,704%	15,070%
<b>2013</b>	53,443%	16,897%	13,069%
<b>2014</b>	49,962%	15,850%	11,342%
<b>2015</b>	54,371%	18,133%	13,980%
<b>2016</b>	53,012%	18,596%	13,777%
<b>2017</b>	47,715%	18,628%	13,995%
<b>2018</b>	53,345%	19,564%	12,550%
<b>2019</b>	55,711%	20,095%	14,650%
<b>2020</b>	54,387%	19,660%	14,850%
<b>2021</b>	53,175%	19,130%	14,410%

Table 10. Survival rates in Poland for stage distant with small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	28,438%	4,851%	3,501%
<b>2001</b>	30,963%	4,378%	3,328%
<b>2002</b>	29,004%	3,737%	2,221%
<b>2003</b>	27,065%	4,910%	3,321%
<b>2004</b>	28,952%	4,592%	3,658%
<b>2005</b>	26,977%	5,391%	4,594%
<b>2006</b>	28,562%	7,039%	5,648%
<b>2007</b>	25,871%	5,845%	4,466%
<b>2008</b>	27,953%	5,976%	4,065%
<b>2009</b>	27,049%	3,814%	2,322%
<b>2010</b>	29,061%	5,454%	3,913%
<b>2011</b>	27,648%	4,027%	2,552%
<b>2012</b>	27,547%	5,359%	3,202%
<b>2013</b>	28,206%	4,947%	2,791%
<b>2014</b>	28,497%	4,936%	2,891%
<b>2015</b>	26,205%	3,009%	1,890%
<b>2016</b>	27,901%	3,872%	1,920%
<b>2017</b>	24,980%	3,542%	1,755%
<b>2018</b>	24,638%	4,054%	1,810%
<b>2019</b>	27,645%	4,720%	1,870%
<b>2020</b>	29,079%	4,750%	2,830%
<b>2021</b>	30,235%	4,330%	2,530%

Table 11. Survival rates in Poland for stage unknown with small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	38,233%	10,281%	6,887%
<b>2001</b>	36,077%	8,674%	5,873%
<b>2002</b>	37,397%	9,477%	6,928%
<b>2003</b>	33,889%	9,920%	7,430%
<b>2004</b>	34,070%	8,992%	6,596%
<b>2005</b>	39,397%	12,853%	10,202%
<b>2006</b>	36,226%	11,550%	9,863%
<b>2007</b>	37,902%	11,436%	8,158%
<b>2008</b>	39,090%	7,743%	5,521%
<b>2009</b>	36,403%	10,453%	7,294%
<b>2010</b>	38,647%	8,141%	5,310%
<b>2011</b>	39,098%	9,790%	7,322%
<b>2012</b>	42,151%	13,084%	10,993%
<b>2013</b>	40,054%	13,162%	9,439%
<b>2014</b>	35,157%	11,720%	7,398%
<b>2015</b>	34,604%	11,500%	9,776%
<b>2016</b>	33,623%	9,481%	7,008%
<b>2017</b>	34,000%	13,661%	10,430%
<b>2018</b>	35,773%	9,066%	7,630%
<b>2019</b>	35,729%	8,703%	11,740%
<b>2020</b>	36,200%	6,860%	5,860%
<b>2021</b>	28,358%	7,730%	4,760%

Table 12. Survival rates in Poland for all stages with non-small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	41,514%	18,972%	15,844%
<b>2001</b>	42,672%	19,696%	15,795%
<b>2002</b>	41,526%	19,814%	15,785%
<b>2003</b>	41,689%	19,636%	15,640%
<b>2004</b>	40,588%	18,532%	14,665%
<b>2005</b>	43,320%	21,128%	17,058%
<b>2006</b>	42,907%	21,298%	17,236%
<b>2007</b>	43,853%	21,815%	17,872%
<b>2008</b>	44,327%	21,501%	17,270%
<b>2009</b>	42,786%	20,742%	16,168%
<b>2010</b>	43,730%	20,521%	16,264%
<b>2011</b>	44,377%	21,611%	16,888%
<b>2012</b>	45,797%	22,483%	17,420%
<b>2013</b>	46,151%	22,061%	16,711%
<b>2014</b>	46,212%	22,880%	17,591%
<b>2015</b>	47,727%	24,294%	19,224%
<b>2016</b>	48,560%	25,610%	20,394%
<b>2017</b>	48,303%	26,075%	20,811%
<b>2018</b>	48,578%	26,222%	18,510%
<b>2019</b>	50,554%	29,160%	20,330%
<b>2020</b>	49,800%	27,010%	21,090%
<b>2021</b>	50,614%	26,870%	21,090%



Table 13. Survival rates in Poland for stage localized + regionalized with non-small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	52,391%	25,913%	21,635%
<b>2001</b>	54,098%	27,190%	21,803%
<b>2002</b>	53,254%	27,756%	21,626%
<b>2003</b>	53,983%	27,621%	22,002%
<b>2004</b>	52,482%	26,426%	20,826%
<b>2005</b>	55,934%	29,020%	23,142%
<b>2006</b>	55,151%	28,883%	22,950%
<b>2007</b>	57,080%	30,120%	24,198%
<b>2008</b>	57,312%	29,916%	23,743%
<b>2009</b>	56,138%	29,624%	23,383%
<b>2010</b>	58,043%	29,607%	23,772%
<b>2011</b>	59,663%	31,817%	25,433%
<b>2012</b>	60,492%	33,188%	26,446%
<b>2013</b>	62,292%	34,577%	26,932%
<b>2014</b>	62,771%	35,626%	27,919%
<b>2015</b>	62,914%	35,892%	28,391%
<b>2016</b>	63,863%	37,993%	30,639%
<b>2017</b>	66,152%	39,981%	32,588%
<b>2018</b>	66,200%	39,378%	28,570%
<b>2019</b>	69,222%	44,707%	30,810%
<b>2020</b>	68,083%	41,410%	32,690%
<b>2021</b>	68,555%	41,900%	33,550%

Table 14. Survival rates in Poland for stage distant with non-small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	25,477%	6,869%	5,086%
<b>2001</b>	25,443%	6,749%	4,485%
<b>2002</b>	23,667%	6,204%	4,704%
<b>2003</b>	23,251%	5,587%	4,011%
<b>2004</b>	23,639%	5,693%	3,760%
<b>2005</b>	25,762%	7,416%	5,378%
<b>2006</b>	25,010%	7,459%	5,731%
<b>2007</b>	24,909%	7,010%	5,125%
<b>2008</b>	25,325%	6,852%	4,874%
<b>2009</b>	23,785%	6,090%	3,761%
<b>2010</b>	24,944%	6,046%	3,636%
<b>2011</b>	25,293%	5,945%	3,232%
<b>2012</b>	26,357%	6,393%	3,540%
<b>2013</b>	27,396%	6,403%	3,420%
<b>2014</b>	26,878%	6,550%	3,699%
<b>2015</b>	26,945%	6,415%	3,931%
<b>2016</b>	26,769%	6,070%	3,493%
<b>2017</b>	26,050%	6,745%	4,006%
<b>2018</b>	26,371%	8,067%	3,100%
<b>2019</b>	27,301%	8,593%	4,210%
<b>2020</b>	29,101%	8,130%	4,930%
<b>2021</b>	30,221%	8,530%	5,100%

Table 15. Survival rates in Poland for stage unknown with non-small cell lung cancer (all ages, men+women), by year

	1-year survival	3-year survival	5-year survival
<b>2000</b>	39,170%	19,289%	16,762%
<b>2001</b>	40,552%	20,138%	17,192%
<b>2002</b>	39,158%	19,767%	16,869%
<b>2003</b>	39,137%	20,565%	16,922%
<b>2004</b>	37,651%	18,482%	15,680%
<b>2005</b>	42,394%	23,786%	20,425%
<b>2006</b>	42,261%	24,403%	20,950%
<b>2007</b>	43,219%	26,117%	23,523%
<b>2008</b>	46,414%	27,179%	23,731%
<b>2009</b>	44,821%	26,162%	21,591%
<b>2010</b>	43,660%	25,179%	21,346%
<b>2011</b>	44,865%	27,674%	23,020%
<b>2012</b>	48,893%	28,715%	23,324%
<b>2013</b>	46,490%	24,440%	19,610%
<b>2014</b>	45,217%	24,916%	20,519%
<b>2015</b>	50,224%	30,043%	25,987%
<b>2016</b>	50,962%	31,753%	27,093%
<b>2017</b>	50,439%	32,580%	27,378%
<b>2018</b>	48,628%	30,961%	25,720%
<b>2019</b>	48,993%	30,644%	25,260%
<b>2020</b>	45,376%	27,910%	22,990%
<b>2021</b>	44,714%	25,690%	21,180%

## 4. Bibliography

- Coviello, E., Seppä, K., Dickman, P. W., & Pokhrel, A. (2015). Estimating Net Survival using a Life-Table Approach. *The Stata Journal: Promoting Communications on Statistics and Stata*, *15*(1), 173–185. <https://doi.org/10.1177/1536867X1501500111>
- Didkowska, J., Barańska, K., Miklewska, M. J., & Wojciechowska, U. (2024). Cancer incidence and mortality in Poland in 2023. *Nowotwory. Journal of Oncology*, *74*(2), 75–93. <https://doi.org/10.5603/njo.99065>
- Perme, M. P., & Pavlic, K. (2018). Nonparametric Relative Survival Analysis with the R Package **reلسurv**. *Journal of Statistical Software*, *87*(8). <https://doi.org/10.18637/jss.v087.i08>

## 5. List of tables

Table 1. Number of patients diagnosed in Poland (all ages, men+women), by stage and year.....	4
Table 2. Number of patients diagnosed with small cell lung cancer in Poland (all ages, men+women), by stage and year.....	5
Table 3. Number of patients diagnosed with non-small cell lung cancer in Poland (all ages, men+women), by stage and year .....	6
Table 4. Survival rates in Poland for all stages (all ages, men+women), by year.....	7
Table 5. Survival rates in Poland for stage localized + regionalized (all ages, men+women), by year ....	8
Table 6. Survival rates in Poland for stage distant (all ages, men+women), by year .....	9
Table 7. Survival rates in Poland for stage unknown (all ages, men+women), by year.....	10
Table 8. Survival rates in Poland for all stages with small cell lung cancer (all ages, men+women), by year.....	11
Table 9. Survival rates in Poland for stage localized + regionalized with small cell lung cancer (all ages, men+women), by year .....	12
Table 10. Survival rates in Poland for stage distant with small cell lung cancer (all ages, men+women), by year .....	13
Table 11. Survival rates in Poland for stage unknown with small cell lung cancer (all ages, men+women), by year .....	14
Table 12. Survival rates in Poland for all stages with non-small cell lung cancer (all ages, men+women), by year .....	15
Table 13. Survival rates in Poland for stage localized + regionalized with non-small cell lung cancer (all ages, men+women), by year .....	16
Table 14. Survival rates in Poland for stage distant with non-small cell lung cancer (all ages, men+women), by year .....	17
Table 15. Survival rates in Poland for stage unknown with non-small cell lung cancer (all ages, men+women), by year .....	18





Warszawa, 2024